Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
Aug 14, 2017 12:15 pm UTC| Business
NORCROSS, Ga., Aug. 14, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended June 30, 2017....
Royale Reports Profit for Second Quarter
Aug 14, 2017 12:12 pm UTC| Business
SAN DIEGO, Aug. 14, 2017 -- Royale Energy, Inc. (OTCQB:ROYL) (“Royale” or the “Company”) today announced its second quarter 2017 results, in which it posted net income of $70,662 for the three months ending June 30,...
Microchip Unveils Next-Generation In-Circuit Debugger with Unparalleled Speed and Flexibility
Aug 14, 2017 12:05 pm UTC| Business
CHANDLER, Ariz., Aug. 14, 2017 -- Microchip Technology Inc. (NASDAQ:MCHP) today announced the MPLAB® ICD 4, an in-circuit programming and debugging development tool for Microchip’s PIC® microcontroller (MCU) and dsPIC®...
ASML reports transactions under its current share buyback program
Aug 14, 2017 12:01 pm UTC| Business
VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average price Total repurchased...
Aug 14, 2017 12:01 pm UTC| Business
HOUSTON, Aug. 14, 2017 -- Spine Injury Solutions, Inc. (OTCQB:SPIN), a technology-driven, medical service, and healthcare solution and financing company servicing the multi-billion dollar spine injury sector, through...
BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017
Aug 14, 2017 12:01 pm UTC| Business
NEW YORK, Aug. 14, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational...
Aug 14, 2017 12:01 pm UTC| Business
Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue Positive efficacy data reported from proof-of-concept Phase 2 VVC study JERSEY CITY, N.J., Aug. 14, 2017 -- SCYNEXIS,...